Document is current

Any future updates will be listed below

A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors

Crossref DOI link: https://doi.org/10.1007/s10549-016-3751-x

Published Online: 2016-03-18

Published Print: 2016-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark